BioInvent's BI-1808-Keytruda Combination Shows 24% Response Rate in Platinum-Resistant Ovarian Cancer Trial
Bitget2026/10/24 07:17- BioInvent reported durable responses with BI-1808 combined with Keytruda in heavily pretreated patients with platinum-resistant ovarian cancer.
- Updated results covering 34 evaluable patients were presented at the ESMO Congress in Madrid on October 24, 2026.
- The chemotherapy-free regimen was generally well tolerated, with manageable immune-related side effects and few treatment-related discontinuations.
- A randomized trial will test BI-1808 added to pembrolizumab and weekly paclitaxel, with optional bevacizumab, against that treatment backbone alone.
- The next stage will enroll 20 patients per arm across three groups, starting in Q1 2027; initial data are expected in H2.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
The Senate takes control, the White House can no longer appoint "its own people", has the Federal Reserve's independence alarm been lifted?
After the Senate changed hands, the White House's room to install its own people at the Federal Reserve has been significantly narrowed. JPMorgan economist Feroli pointed out that the only expiring Federal Reserve Board position in the next two years is Powell's chairmanship (January 2028). If the White House wants to fill it, it must nominate a candidate acceptable to the Democratic-controlled Senate; otherwise, the seat will remain vacant. Meanwhile, the political value of removing Board member Cook has therefore diminished, and current Chair Waller's path to reappointment is also facing new congressional public relations pressure.
Crypto prices
More
